It’s been a little over two years since the Inflation Reduction Act (IRA) was enacted. During this period, the first ten products have been negotiated with CMS, health plans have adapted to new fiscal responsibilities, and manufacturers have rethought their pipeline strategies and product launches. Additionally, state-level Prescription Drug Affordability Boards (PDABs) have emerged, aiming to reduce costs and hold manufacturers accountable for affordability. To add to these changes, we’ve had a change in the White House and it is likely that President Trump will wish to put his own stamp on pharmaceutical pricing reform.
We invite you to a CRA-moderated panel discussion where experts will reflect on how recent state and Federal pricing policies are shaping US pricing and market access strategies for life science companies. Key discussion topics will include:
- The macro-level impact of state and federal price control policies on US pharmaceutical pricing.
- The evolution of health plans and PBM formularies and utilization management strategies in response to increased responsibilities.
- The effects of negotiated prices and out-of-pocket cost caps on patient access to medicines.
- How manufacturers are adapting their pricing and access strategies for success.
- Expected pharmaceutical pricing policy changes under the next administration
Tuesday, January 14, 2025 | 7:30am – 9:30am PST
7:30am – Registration and breakfast
8:00am – Panel begins
Panelists:
Alice Chen: Alice is an Associate Professor of Public Policy and Vice Dean for Research at the USC Sol Price School of Public Policy. Her research focuses on improving the efficiency of health care markets. She studies the impact of regulation on pharmaceutical markets, provider responses to financial incentives, and the role of health care spending on health and labor market outcomes.
Frank David, MD, PhD: Frank is the Founder and Managing Director of Pharmagellan and Professor of the Practice of Biotechnology at Tufts University. In his consulting practice, he helps drug developers and investors understand the relationship between clinical development strategy and regulatory, commercial, and corporate financial considerations. He is the author of two books on biotech valuation and clinical trial analysis.
Rhett Johnson: Rhett is a Vice President at Charles River Associates. He has over 25 years of consulting experience, assisting life sciences clients develop commercialization strategies that generate a sustainable competitive advantage in a complex and constantly evolving healthcare marketplace. Areas of focus include corporate growth strategy, asset evaluations and product strategy, pricing and market access, analytics and forecasting, and competitive analysis.
Peter Pitts: Peter is a globally recognized healthcare policy expert and former Associate Commissioner of the US Food & Drug Administration (FDA), with a distinguished career spanning public health policy, regulatory affairs, and strategic healthcare initiatives. With an unwavering commitment to improving global health systems, Peter brings a unique blend of government, academic, and private sector expertise to boardrooms worldwide.
Moderator:
Kirsten Axelsen: Kirsten is a Senior Policy Advisor at Charles River Associates. She works with leaders in healthcare helping to develop business practices that lead to greater access to affordable medicines, positive public perception, and sustained profitability to support investment in the next generation of innovation.
If you’re interested, click here to request an invitation.
